Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects with moderately to severely active rheumatoid arthritis~* Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify)~* Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline~* Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening~* Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab)~Exclusion Criteria:~* Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva)~* Subject has been treated with intra-articular or parenteral administration of corticosteroids within 4 weeks of screening~* Subject has diagnosis or history of gout or pseudogout~* Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound)~* Subject has history of chronic arthritis diagnosed before age 16 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab + Low Dose Methotrexate (Type: EXPERIMENTAL): Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
- Adalimumab + High Dose Methotrexate (Type: ACTIVE_COMPARATOR): Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).

Based on this trial design, predict the completion outcome and termination type (if applicable).